Compare ACADIA Pharmaceuticals Inc. (ACAD) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs QUALCOMM, Inc. — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while QUALCOMM, Inc. trades at $185.09 (market cap $192.85B). The key difference: QUALCOMM, Inc. is far larger — about 43× ACADIA Pharmaceuticals Inc.'s market cap, and QUALCOMM, Inc. pays a 2.01% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | QCOM | |
|---|---|---|
Market Cap | $4.49B | $192.85B |
Sector | Health | Technology |
52-Week High | $28.06 | $251.10 |
52-Week Low | $20.06 | $124.07 |
Enterprise Value | $3.69B | $198.32B |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Qualcomm (QCOM) trades at $186.48, up 5.8% in the last 24 hours, reflecting strong momentum. The stock exhibits a bearish technical signal but has consistently beaten earnings expectations in recent quarters. Revenue for 2025 reached $44.28 billion, with a net income margin of 22.31%, though this represents a decline from the previous year. The company is actively diversifying into AI, automotive, and data centers, as highlighted at recent industry events like COMPUTEX 2026.
The outlook is mixed; analyst consensus is a 'Buy' with a $221.21 price target, indicating potential upside, but near-term risks include margin pressures and intense competition in the PC and smartphone chip markets. The stock's valuation, with a P/E of 20.05, appears reasonable relative to growth prospects, but investors must weigh the diversification strategy against persistent market softness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
